Literature DB >> 19834431

Contact dermatitis due to topical drugs.

A Barbaud1.   

Abstract

The management of patients who have developed a contact dermatitis due to topical drugs requires to stop the suspected drug application, to treat the patient with corticosteroid ointments, to perform dermatoallergological investigations e.g. drug patch tests in case of contact eczema and diluted prick tests in case of contact urticaria in order to determine whether the adverse drug reaction was due to excipients or to the drug itself. Patients with chronic leg ulcers have a high risk of contact dermatitis to topical drugs and to antiseptics. It is necessary to advise the patient concerning the avoidance of topical but also systemic readministration of the responsible molecule. An excipient responsible in inducing a contact sensitization to a topical drug can also be found in cosmetics, the name of the responsible excipient has to be given to the patient under the common name but also under the INCI name. In most of the cases there is no risk in systemically administering iodine, sulfites or vehicles in a sensitized patient who had developed a contact dermatitis to topical medications. When the drug itself is responsible in inducing a contact allergy it is necessary to determine if cross reactions with other drugs can occur and if the responsible molecule can induce systemic cutaneous adverse drug reactions if the drug is systemically readministered. Among NSAID there is no cross reactions between bufexamac and diclofenac, between salicylamide, glycol salicylate, salicylic acid and acetylsalicylic acid. In case of photosensitization 1) to ketoprofen or 2) piroxicam the topical and/or systemic administration of the following molecules are contraindicated with respectively 1) ketoprofen, tiaprofenic acid, fenofibrate, oxybenzone or 2) piroxicam, thimerosal. A patient sensitized to corticosteroid ointment has to be tested in order to determine which corticosteroid classes are sensitizing. The topical and systemic administrations of molecules belonging to the sensitizing classes (A, B, C, D1 or D2) have to be forbidden.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19834431

Source DB:  PubMed          Journal:  G Ital Dermatol Venereol        ISSN: 0392-0488            Impact factor:   2.011


  3 in total

1.  Transdermal diclofenac patches for control of post-extraction pain. Pilot randomized controlled double-blind study.

Authors:  Sriram Krishnan; Pankaj Sharma; Rakesh Sharma; Suman Kumar; Mahesh Verma; Zainab Chaudhary
Journal:  Oral Maxillofac Surg       Date:  2013-07-14

Review 2.  Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice?

Authors:  Marek L Kowalski; Joanna S Makowska
Journal:  Allergy Asthma Immunol Res       Date:  2015-03-05       Impact factor: 5.764

3.  Medicated adhesive dressing is a safe and non-inferior cutaneous seal as compared to compound tincture benzoin dermal seal for percutaneous interventions.

Authors:  Rudradatt C Parmar; Dhruvkumar M Patel; Mukundkumar V Patel; Bhagirath B Solanki; Maitri M Patel; Jayanti K Gurumukhani; Himil J Mahadevia; Rohan A Gajjar; Parth R Patel
Journal:  J Family Med Prim Care       Date:  2019-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.